|IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data|
D Wang, L Yan, Q Hu, LE Sucheston, MJ Higgins, CB Ambrosone, ...
Bioinformatics 28 (5), 729-730, 2012
|Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis|
JD Waight, C Netherby, ML Hensen, A Miller, Q Hu, S Liu, PN Bogner, ...
The Journal of clinical investigation 123 (10), 4464-4478, 2013
|Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism|
JD Waight, Q Hu, A Miller, S Liu, SI Abrams
PloS one 6 (11), e27690, 2011
|Replication of associations between genetic polymorphisms and chronic graft-versus-host disease|
Blood 128 (20), 2450-2456, 2016
|Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators|
L Wei, J Wang, E Lampert, S Schlanger, AD DePriest, Q Hu, EC Gomez, ...
European urology 71 (2), 183-192, 2017
|Circulating miR-148b and miR-133a as biomarkers for breast cancer detection|
J Shen, Q Hu, M Schrauder, L Yan, D Wang, L Medico, Y Guo, S Yao, ...
Oncotarget 5 (14), 5284, 2014
|Low 25 (OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia|
HJ Lee, JR Muindi, W Tan, Q Hu, D Wang, S Liu, GE Wilding, LA Ford, ...
Cancer 120 (4), 521-529, 2014
|Large-scale, ion-current-based proteomics investigation of bronchoalveolar lavage fluid in chronic obstructive pulmonary disease patients|
C Tu, MJ Mammen, J Li, X Shen, X Jiang, Q Hu, J Wang, S Sethi, J Qu
Journal of proteome research 13 (2), 627-639, 2014
|Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients|
PK Singh, L Preus, Q Hu, L Yan, MD Long, CD Morrison, M Nesline, ...
Oncotarget 5 (3), 824, 2014
|Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer|
JS Kirk, K Schaarschuch, Z Dalimov, E Lasorsa, SY Ku, S Ramakrishnan, ...
Oncotarget 6 (5), 3136, 2015
|KLF9 is a novel transcriptional regulator of bortezomib-and LBH589-induced apoptosis in multiple myeloma cells|
S Mannava, DZ Zhuang, JR Nair, R Bansal, JA Wawrzyniak, SN Zucker, ...
Blood 119 (6), 1450-1458, 2012
|Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry|
CB Ambrosone, AC Young, LE Sucheston, D Wang, Y Li, S Liu, L Tang, ...
Oncotarget 5 (1), 237, 2014
|Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction|
DK Wells, MM van Buuren, KK Dang, VM Hubbard-Lucey, KCF Sheehan, ...
Cell 183 (3), 818-834. e13, 2020
|Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant|
E Karaesmen, AA Rizvi, LM Preus, PL McCarthy, MC Pasquini, K Onel, ...
Blood, The Journal of the American Society of Hematology 130 (13), 1585-1596, 2017
|An IonStar experimental strategy for MS1 ion current-based quantification using ultrahigh-field orbitrap: reproducible, in-depth, and accurate protein measurement in large cohorts|
X Shen, S Shen, J Li, Q Hu, L Nie, C Tu, X Wang, B Orsburn, J Wang, J Qu
Journal of proteome research 16 (7), 2445-2456, 2017
|Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis|
YW Li, H Shen, C Frangou, N Yang, J Guo, B Xu, W Bshara, L Shepherd, ...
Cell cycle 14 (1), 146-156, 2015
|IonStar enables high-precision, low-missing-data proteomics quantification in large biological cohorts|
X Shen, S Shen, J Li, Q Hu, L Nie, C Tu, X Wang, DJ Poulsen, BC Orsburn, ...
Proceedings of the National Academy of Sciences 115 (21), E4767-E4776, 2018
|OSAT: a tool for sample-to-batch allocations in genomics experiments|
L Yan, C Ma, D Wang, Q Hu, M Qin, JM Conroy, LE Sucheston, ...
BMC genomics 13 (1), 1-7, 2012
|Entinostat, a novel histone deacetylase inhibitor is active in B‐cell lymphoma and enhances the anti‐tumour activity of rituximab and chemotherapy agents|
S Frys, Z Simons, Q Hu, MJ Barth, JJ Gu, C Mavis, J Skitzki, L Song, ...
British journal of haematology 169 (4), 506-519, 2015
|NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis|
CR Jeter, B Liu, Y Lu, HP Chao, D Zhang, X Liu, X Chen, Q Li, K Rycaj, ...
Cell discovery 2 (1), 1-19, 2016